

Client Reference: 2000-30-0178A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re the Application of

NABIL HANNA

Group Art Unit: 1642

Examiner: Larry R. Helms

Application No.: 09/822,672

Filed: April 2, 2001

Confirmation No.: 9345

RECEIVED

DEC 31 2003

TECH CENTER 1600/2900

For: COMBINED USE OF ANTI-CYTOKINE ANTIBODIES OR ANTAGONISTS AND
ANTI-CD20 FOR THE TREATMENT OF B CELL LYMPHOMA

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 CFR 1.56, the attention of the Patent and Trademark Office is hereby directed to the reference(s) listed on the attached PTO-1449. Unless otherwise indicated herein, one copy of each reference is attached. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is being filed after filing a request for continued examination AND before receipt of a subsequent official action on the merits. No certification or fee is required.

Respectfully Submitted,



Thomas A. Cawley, Jr., Ph.D.,
Registration Number 40944

Date: December 24, 2003
PILLSBURY WINTHROP LLP
Telephone: (703) 905-2000
Facsimile: (703) 905-2500
P.O. Box 10500
McLean, VA 22102
TAC/JBM:ntb

Atty. Dkt. No.	M#	Client Ref.
	0280062	2000-30-0178A

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

Applicant: HANNA.

Appln. No.: 09/822,672

Filing Date: April 2, 2001

Date: December 24, 2003 Page 1 of 1

Examiner: Larry Helms Group Art Unit: 1642

U.S. PATENT DOCUMENTS

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date
	AR 6,183,744 B1	02/2001	Goldenberg			
	BR 6,306,393 B1	10/2001	Goldenberg			
	CR					
	DR					
	ER					
	FR					

RECEIVED

DEC 31 2003

TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

	Document Number	Date MM/YYYY	Country	Inventor Name	English Abstract	Translation Readily Available
	GR					
	HR					
	IR					
	JR					
	KR					
	LR					

OTHER

MR	Kaminski, et al., "Radioimmunotherapy of Advanced B-Cell Lymphoma with Non Bone Marrow Ablative Doses of 131-I MB-1 Antibody," 1990, <i>Antibody Immunoconjugates, and Radiopharmaceuticals</i> , Vol. 3, No. 1, Abstract No. 83.
NR	Kaminski, et al., "Radioimmunodetection (RID) and Non Marrow Ablative Radioimmunotherapy (RIT) of B-Cell Lymphoma With 131-I MB-1 Antibody," 1990, <i>Proceedings of ASCO</i> , Vol. 9, p. 271, Abstract No. 1051.
OR	Wahl, et al., "Radioimmunotherapy of B-Cell Lymphoma with 131 MB-1 Monoclonal Antibody," <i>The Journal of Nuclear Medicine: Proceedings of the 37th Annual Meeting</i> , p. 852, Abstract No. 622.
PR	Kaminski, et al., "Phase I Trial Results of 131-I MB-1 Antibody Radioimmunotherapy (RAIT) of B-Cell Lymphoma," 1990, <i>Antibody Immunoconjugates, and Radiopharmaceuticals</i> , Vol. 4, No. 1, p. 36, Abstract No. 66.
QR	Kaminski, et al., "Phase I Evaluation of 131-I MB-1 Antibody Radioimmunotherapy (RIT) of B-Cell Lymphoma," 1990, <i>Blood</i> , Vol. 76, No. 10, p. 355a, Abstract No. 1409.
RR	Kaminski, et al., "Imaging, Dosimetry, and Radioimmunotherapy With Iodine 131-Labeled Anti-CD37 Antibody in B-Cell Lymphoma," 1992, <i>Journal of Clinical Oncology</i> , Vol. 10, No. 11, pp. 1696-1711.
SR	Jensen, et al., "Rapid tumor lysis in a patient with B-cell chronic lymphocytic leukemia and lymphocytosis treated with an anti-CD20 monoclonal antibody (IDEC C2B8, rituximab)," 1998, <i>Ann Hematol</i> , Vol. 77, pp. 89-91.
TR	

Examiner

Date Considered:

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.